跳至主要内容
临床试验/EUCTR2013-004313-41-NL
EUCTR2013-004313-41-NL进行中(未招募)1 期

Effect of pre-operative pain treatment by means of duloxetine on postoperative outcome after total hip or knee arthroplasty - Duloxetine In OsteoArthritis study (DOA-study)

MCG0 个研究点开始时间: 2014年2月24日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Primary Osteoarthritis (based on clinical and radiological ACR-criteria)
  • 2.Age >18 years
  • 3.A neuropathic or at least a mixed neuropathic / noiciceptive pain phenotype (m-painDETECT-score >12)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 49
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • General exclusion criteria:
  • 1.Surgical hip or knee joint procedures less than 1 year previously
  • 2.Cognitive and/or neurological disorders that could interfere strongly with questionnaire surveys (e.g. Dementia)
  • 3.Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation.
  • 4.Planned or intended to perform THA or TKA within the study duration (present planned arthroplasty not included)
  • 5.A history of peripheral nerve injury
  • 6.Previous exposure to Duloxetine
  • Duloxetine related exclusion criteria:
  • 7.Allergy to study medication or compounds of the Duloxetine capsule (or another SNRI);
  • 8.History of peptic ulcer disease or bleeding disorder (or other substantial risk factor for bleeding)
  • 9.Psychiatric disorders, other than depression;
  • 10.Severe depression (HADS score >15 on depression subscale);
  • 11.A history of alcohol or other substance abuse (excluding nicotine and caffeine) or dependence within the five years prior to enrollment;
  • 12.Currently pregnant or lactating, our planned to become pregnant within the study period
  • 13.History of cardiac arrhythmias, cardiac failure, myocardial infarct;
  • 14.impaired function of the liver, or known cirrhosis or liver transplantation;
  • 15.severe renal impairment, or had renal transplantation or receiving renal dialysis;
  • 16.Hyponatraemia, or a history of frequent hyponatremias;
  • 17.History of uncontrolled hypertension, history of glaucoma (or with increased intraocular pressure) ,uncontrolled thyroid disease and a history of uncontrolled seizures;
  • 18.Usage of non selective monoamine oxidase (MAO) inhibitors, TCA’s , SSRIs, SNRIs in the last year;
  • 19.Usage of strong CYP1A2-inhibitors

研究者

发起方
MCG

相似试验